Brand Name
Austedo
Generic Name
Deutetrabenazine
View Brand Information FDA approval date: April 12, 2017
Form: Tablet, Kit
What is Austedo (Deutetrabenazine)?
AUSTEDO ® is indicated in adults for the treatment of: chorea associated with Huntington’s disease [see Clinical Studies ( 1.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
A Phase 4, Open-Label Study to Evaluate the Efficacy of Valbenazine on Clinician- and Patient-Reported Outcomes in Patients With Tardive Dyskinesia (TD) Who Remain Symptomatic While on Deutetrabenazine or After Discontinuing Prior TD Treatment With a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Summary: This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.